Novavax (NVAX) Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
NVAX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.37 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 2.43 |
| 1 Month Change | 2.95% |
| 3 Month Change | 14.99% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVAX | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -4.9% | -4.8% | -1.4% |
| 1Y | n/a | 40.0% | 16.0% |
Return vs Industry: Insufficient data to determine how NVAX performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how NVAX performed against the Swiss Market.
Price Volatility
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 2.1% |
Stable Share Price: NVAX's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: NVAX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 749 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
Novavax, Inc. Fundamentals Summary
| NVAX fundamental statistics | |
|---|---|
| Market cap | CHF 1.24b |
| Earnings (TTM) | -CHF 71.03m |
| Revenue (TTM) | CHF 482.21m |
Is NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVAX income statement (TTM) | |
|---|---|
| Revenue | US$596.34m |
| Cost of Revenue | US$432.38m |
| Gross Profit | US$163.96m |
| Other Expenses | US$251.79m |
| Earnings | -US$87.83m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 27.49% |
| Net Profit Margin | -14.73% |
| Debt/Equity Ratio | -201.0% |
How did NVAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 04:13 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novavax, Inc. is covered by 23 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| David Lebowitz | Brean Capital Historical (Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |